局部晚期-话题@MedSci

#局部晚期#

176篇内容 | 3353人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1650772, encodeId=876a1650e72ad, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=NMPA批准百济神州的抗PD-1单抗替雷利珠，用于治疗局部晚期或转移性尿道上皮癌, objectType=article, longId=192250, objectId=940019225097, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=940019225097, replyNumber=0, likeNumber=67, createdTime=2021-02-22, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=940019225097, moduleTitle=NMPA批准百济神州的抗PD-1单抗替雷利珠，用于治疗局部晚期或转移性尿道上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=940019225097)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650763, encodeId=4b691650e6378, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=局部晚期胃癌优化治疗模式的探寻, objectType=article, longId=181034, objectId=0902181034b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0902181034b7, replyNumber=0, likeNumber=69, createdTime=2020-03-02, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0902181034b7, moduleTitle=局部晚期胃癌优化治疗模式的探寻, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0902181034b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650766, encodeId=73bb1650e664b, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=PD-1单抗单药治疗双原发癌，局部晚期肺鳞癌肿瘤疗效PR，肝细胞癌肿瘤疗效评估pCR, objectType=article, longId=184137, objectId=74cc18413e05, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74cc18413e05, replyNumber=0, likeNumber=114, createdTime=2020-03-29, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74cc18413e05, moduleTitle=PD-1单抗单药治疗双原发癌，局部晚期肺鳞癌肿瘤疗效PR，肝细胞癌肿瘤疗效评估pCR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74cc18413e05)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650765, encodeId=f0921650e6571, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始, objectType=article, longId=181869, objectId=b55d181869fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b55d181869fc, replyNumber=0, likeNumber=79, createdTime=2020-06-18, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b55d181869fc, moduleTitle=Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b55d181869fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650757, encodeId=fd3a1650e571a, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=开启局部晚期肺癌治疗“新模式”——听吴一龙教授解读CTONG1103研究发现, objectType=article, longId=170144, objectId=32b91e014439, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32b91e014439, replyNumber=0, likeNumber=61, createdTime=2019-12-08, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32b91e014439, moduleTitle=开启局部晚期肺癌治疗“新模式”——听吴一龙教授解读CTONG1103研究发现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32b91e014439)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650768, encodeId=55a21650e6843, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, objectType=article, longId=185843, objectId=5f5518584350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f5518584350, replyNumber=0, likeNumber=86, createdTime=2020-09-04, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f5518584350, moduleTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f5518584350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650751, encodeId=b35d1650e51f9, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=仑伐替尼联合来曲唑在绝经后HR+局部晚期/转移性乳腺癌中的探索, objectType=article, longId=166861, objectId=f28a1668612c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f28a1668612c, replyNumber=0, likeNumber=60, createdTime=2019-12-28, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f28a1668612c, moduleTitle=仑伐替尼联合来曲唑在绝经后HR+局部晚期/转移性乳腺癌中的探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f28a1668612c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650755, encodeId=4c511650e550a, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=J Clin Oncol:局部晚期肺癌新希望——JCO发表CTONG 1103靶向-手术-靶向多中心研究成果, objectType=article, longId=168698, objectId=ca0c168698eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca0c168698eb, replyNumber=0, likeNumber=67, createdTime=2019-11-03, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca0c168698eb, moduleTitle=J Clin Oncol:局部晚期肺癌新希望——JCO发表CTONG 1103靶向-手术-靶向多中心研究成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca0c168698eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650756, encodeId=ceb21650e56eb, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=靶向治疗开启局部晚期肺癌治疗“新模式”，靶向-手术-靶向降低61%肺癌复发风险, objectType=article, longId=168748, objectId=b7aa168e4877, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7aa168e4877, replyNumber=0, likeNumber=76, createdTime=2020-04-09, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7aa168e4877, moduleTitle=靶向治疗开启局部晚期肺癌治疗“新模式”，靶向-手术-靶向降低61%肺癌复发风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7aa168e4877)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650771, encodeId=ac511650e7142, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=欧洲药品管理局批准了Seattle Genetics公司的tucatinib用于局部晚期或转移性HER2阳性乳腺癌患者的市场授权申请, objectType=article, longId=187241, objectId=618618e241e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=618618e241e2, replyNumber=0, likeNumber=78, createdTime=2020-06-30, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=618618e241e2, moduleTitle=欧洲药品管理局批准了Seattle Genetics公司的tucatinib用于局部晚期或转移性HER2阳性乳腺癌患者的市场授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=618618e241e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650762, encodeId=30fc1650e621e, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=JAMA Surg：腹腔镜远端胃切除术联合新辅助化疗治疗局部晚期胃癌, objectType=article, longId=180291, objectId=a7cc180291c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7cc180291c5, replyNumber=0, likeNumber=55, createdTime=2020-03-24, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7cc180291c5, moduleTitle=JAMA Surg：腹腔镜远端胃切除术联合新辅助化疗治疗局部晚期胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7cc180291c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650750, encodeId=7f7d1650e50f9, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=手术治疗局部晚期原发性胸腺腺癌一例, objectType=article, longId=166488, objectId=944f16648827, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=944f16648827, replyNumber=0, likeNumber=90, createdTime=2019-09-20, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=944f16648827, moduleTitle=手术治疗局部晚期原发性胸腺腺癌一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=944f16648827)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650767, encodeId=83bc1650e677a, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=JAMA Surg：新辅助化疗后腹腔镜远端局部晚期胃癌的疗效, objectType=article, longId=185410, objectId=e22b185410d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e22b185410d3, replyNumber=0, likeNumber=51, createdTime=2020-03-06, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e22b185410d3, moduleTitle=JAMA Surg：新辅助化疗后腹腔镜远端局部晚期胃癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e22b185410d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650764, encodeId=68941650e6416, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=【2019 ESMO】放化疗联合帕博利珠单抗治疗局部晚期食管鳞癌, objectType=article, longId=181035, objectId=c7c318103504, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7c318103504, replyNumber=0, likeNumber=78, createdTime=2019-12-13, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7c318103504, moduleTitle=【2019 ESMO】放化疗联合帕博利珠单抗治疗局部晚期食管鳞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7c318103504)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650753, encodeId=69a81650e530f, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=局部晚期直肠癌术前化放疗效果有望翻番, objectType=article, longId=168152, objectId=7008168152dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7008168152dc, replyNumber=0, likeNumber=84, createdTime=2019-11-29, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7008168152dc, moduleTitle=局部晚期直肠癌术前化放疗效果有望翻番, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7008168152dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650754, encodeId=44441650e541c, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=NEJM：辅助化疗加放射治疗局部晚期子宫内膜癌, objectType=article, longId=168303, objectId=13e216830312, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13e216830312, replyNumber=0, likeNumber=56, createdTime=2019-12-10, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13e216830312, moduleTitle=NEJM：辅助化疗加放射治疗局部晚期子宫内膜癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13e216830312)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650761, encodeId=f2e81650e61c8, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查, objectType=article, longId=179625, objectId=df171e962513, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df171e962513, replyNumber=0, likeNumber=61, createdTime=2019-12-10, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df171e962513, moduleTitle=Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df171e962513)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650744, encodeId=2eff1650e448b, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=局部晚期直肠癌转化治疗病例, objectType=article, longId=152394, objectId=061315239446, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=061315239446, replyNumber=0, likeNumber=70, createdTime=2019-01-10, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=061315239446, moduleTitle=局部晚期直肠癌转化治疗病例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=061315239446)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650747, encodeId=688b1650e47a6, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=JCO：地塞瑞克与曲普瑞林治疗局部晚期内分泌反应性乳腺癌：随机II期试验, objectType=article, longId=157059, objectId=a02715e05966, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a02715e05966, replyNumber=0, likeNumber=79, createdTime=2019-12-01, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a02715e05966, moduleTitle=JCO：地塞瑞克与曲普瑞林治疗局部晚期内分泌反应性乳腺癌：随机II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a02715e05966)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650739, encodeId=c1481650e39be, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌, objectType=article, longId=149623, objectId=297e149623e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=297e149623e6, replyNumber=0, likeNumber=67, createdTime=2019-01-07, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=297e149623e6, moduleTitle=阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=297e149623e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

局部晚期

2020-05-29

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

NMPA批准百济神州的抗PD-1单抗替雷利珠，用于治疗局部晚期或转移性尿道上皮癌

2021-02-22

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

局部晚期胃癌优化治疗模式的探寻

2020-03-02

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

PD-1单抗单药治疗双原发癌，局部晚期肺鳞癌肿瘤疗效PR，肝细胞癌肿瘤疗效评估pCR

2020-03-29

柳叶一刀 (审核中...)

前往app查看评论内容

#局部晚期#

Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始

2020-06-18

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

开启局部晚期肺癌治疗“新模式”——听吴一龙教授解读CTONG1103研究发现

2019-12-08

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点

2020-09-04

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

仑伐替尼联合来曲唑在绝经后HR+局部晚期/转移性乳腺癌中的探索

2019-12-28

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

J Clin Oncol:局部晚期肺癌新希望——JCO发表CTONG 1103靶向-手术-靶向多中心研究成果

2019-11-03

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

靶向治疗开启局部晚期肺癌治疗“新模式”，靶向-手术-靶向降低61%肺癌复发风险

2020-04-09

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

欧洲药品管理局批准了Seattle Genetics公司的tucatinib用于局部晚期或转移性HER2阳性乳腺癌患者的市场授权申请

2020-06-30

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

JAMA Surg：腹腔镜远端胃切除术联合新辅助化疗治疗局部晚期胃癌

2020-03-24

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

手术治疗局部晚期原发性胸腺腺癌一例

2019-09-20

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

JAMA Surg：新辅助化疗后腹腔镜远端局部晚期胃癌的疗效

2020-03-06

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

【2019 ESMO】放化疗联合帕博利珠单抗治疗局部晚期食管鳞癌

2019-12-13

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

局部晚期直肠癌术前化放疗效果有望翻番

2019-11-29

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

NEJM：辅助化疗加放射治疗局部晚期子宫内膜癌

2019-12-10

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查

2019-12-10

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

局部晚期直肠癌转化治疗病例

2019-01-10

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

JCO：地塞瑞克与曲普瑞林治疗局部晚期内分泌反应性乳腺癌：随机II期试验

2019-12-01

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌

2019-01-07

科室
- - 订阅+
  - 更多科室
工具
服务